natgillin/translations-raw huggingface dataset:
Patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses in one tablet once daily. .
Bolniki, ki jemljejo telmisartan in amlodipin v dveh ločenih tabletah, lahko začnejo enkrat na dan jemati tablete zdravila Twynsta, ki vsebujejo enaka odmerka obeh učinkovin v eni tableti.
Patients receiving Temodal in combination with radiotherapy may experience different side effects than patients taking Temodal alone.
Pri bolnikih, ki zdravilo Temodal prejemajo v kombinaciji z radioterapijo se lahko pojavijo drugačni neželeni učinki, kot pri bolnikih, ki prejemajo samo zdravilo Temodal.
Patients receiving Temodal in combination with radiotherapy may experience different side effects than patients using Temodal alone.
Pri bolnikih, ki zdravilo Temodal prejemajo v kombinaciji z radioterapijo se lahko pojavijo drugačni neželeni učinki, kot pri bolnikih, ki prejemajo samo zdravilo Temodal.
Patients receiving Temomedac in combination with radiotherapy may experience different side effects than patients taking Temomedac alone.
Pri bolnikih, ki zdravilo Temomedac prejemajo v kombinaciji z radioterapijo se lahko pojavijo drugačni neželeni učinki, kot pri bolnikih, ki prejemajo samo zdravilo Temomedac.
Patients receiving Temozolomide SUN in combination with radiotherapy may experience different side effects from patients taking Temozolomide SUN alone.
Bolniki, ki jemljejo zdravilo Temozolomid SUN v kombinaciji z obsevanjem, lahko doživijo drugačne neželene učinke kot tisti, ki jemljejo samo zdravilo Temozolomid SUN.
Patients receiving Temozolomide Teva in combination with radiotherapy may experience different side effects than patients taking Temozolomide Teva alone.
Bolniki, ki se zdravijo z zdravilom Temozolomide Teva v kombinaciji z obsevanjem, lahko doživijo drugačne neželene učinke kot tisti, ki jemljejo samo Temozolomide Teva.
Patients receiving tenofovir should
Bolnike, ki se zdravijo s
Patients receiving the 0.75 mg/kg bw twice-daily dose or the 1 mg/kg bw twice-daily dose should not receive the second enoxaparin dose in the twice-daily regimen to allow a longer delay before catheter placement or removal.
Pri bolnikih, ki prejemajo 0,75 mg/kg TM dvakrat na dan ali 1 mg/kg TM dvakrat na dan, je treba izpustiti drugi odmerek enoskaparina v tem režimu, da zagotovimo daljši odlog pred namestitvijo ali odstranitvijo katetera.
Patients receiving the 0.75 mg/kg bw twice-daily dose or the 1 mg/kg bw twice-daily dose should not receive the second enoxaparin dose in the twice-daily regimen to allow a longer delay before catheter placement or removal.
Pri bolnikih, ki prejemajo 0,75 mg/kg TM dvakrat na dan ali 1 mg/kg TM dvakrat na dan, morate izpustiti drugi odmerek enoskaparina v tem režimu, da zagotovite daljši odlog pred namestitvijo ali odstranitvijo katetera.
Patients receiving the following medicinal products should be treated with caution (see section 4.5):
Posebna previdnost je potrebna pri bolnikih, ki prejemajo katero od naslednjih navedenih zdravil (glejte poglavje 4.5):
Patients receiving the lower dose of Ruconest had the option of receiving a second dose up to four hours after the first.
Bolniki, ki so prejeli manjši odmerek zdravila Ruconest, so imeli možnost prejeti drugi odmerek do štiri ure po prvem odmerku.
Patients receiving the modified-release levodopa/carbidopa medicinal product initiated treatment at 95 mg levodopa/23.75 mg carbidopa three times daily (TID).
Pri bolnikih, ki so prejemali zdravilo s prirejenim sproščanjem, ki vsebuje levodopo/karbidopo, se je zdravljenje začelo z odmerkom 95 mg levodope/23,75 mg karbidope trikrat na dan.
Patients receiving the starting dose of 175 mg weekly for the treatment of MCL must be followed closely to decide on dose reductions/delays.
Bolnike, ki prejmejo začetni odmerek 175 mg na teden za zdravljenje MCL, moramo skrbno spremljati, da se lahko odločimo za zmanjšanja/zakasnitve odmerka.
Patients receiving Tredaptive, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9 % were also taking ezetimibe [10 mg].
Bolniki, ki so dobivali zdravilo Tredaptive, nikotinsko kislino (pripravek s podaljšanim sproščanjem), ali placebo, so jemali tudi statine (29 % atorvastatin [5–80 mg], 54 % simvastatin [10–80 mg], 17 % druge statine [2,5–180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)) in 9 % od teh jih je jemalo tudi ezetimib [10 mg].
Patients receiving Trevaclyn, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9 % were also taking ezetimibe [10 mg].
Bolniki, ki so dobivali zdravilo Trevaclyn, nikotinsko kislino (pripravek s podaljšanim sproščanjem), ali placebo, so jemali tudi statine (29 % atorvastatin [5–80 mg], 54 % simvastatin [10–80 mg], 17 % druge statine [2,5–180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)) in 9 % od teh jih je jemalo tudi ezetimib [10 mg].
Patients receiving Vectibix in combination with the IFL regimen [bolus 5-fluorouracil (500 mg/m2), leucovorin (20 mg/m2) and irinotecan (125 mg/m2)] experienced a high incidence of severe diarrhoea (see section 4.8).
Bolniki, ki so dobivali zdravilo Vectibix v kombinaciji z IFL shemo [bolus 5-fluorouracila (500 mg/m2), levkovorina (20 mg/m2) in irinotekana (125 mg/m2)], so zelo pogosto dobili hudo drisko (glejte poglavje 4.8).
Patients receiving VIRACEPT BID (n=10) achieved nelfinavir Cmax of 4.0  0.8 µg/ml and morning and evening trough concentrations of 2.2  1.3 µg/ml and 0.7  0.4 µg/ml, respectively.
Pri bolnikih, ki so prejemali zdravilo VIRACEPT dvakrat na dan (n = 10), je bila Cmax nelfinavirja v plazmi 4,0 ± 0,8 μg/ml, najnižje koncentracije v plazmi pred naslednjim odmerkom zjutraj 2,2 ± 1,3 μg/ml in zvečer 0,7 ± 0,4 μg/ml.
Patients receiving VIRACEPT TID (n=11) achieved nelfinavir peak plasma concentrations (Cmax) of 3.0  1.6 µg/ml and morning and evening trough concentrations of 1.4  0.6 µg/ml and 1.0  0.5 µg/ml, respectively.
Pri bolnikih (n = 11), ki so zdravilo VIRACEPT prejemali trikrat na dan, so bile največje koncentracije nelfinavirja v plazmi (Cmax) 3,0 ± 1,6 μg/ml, najnižje koncentracije pred naslednjim odmerkom zjutraj 1,4 ± 0,6 μg/ml in zvečer 1,0 ± 0,5 μg/ml.
Patients receiving Zerit should be frequently examined and questioned for signs of lipoatrophy.
Bolnike, ki prejemajo zdravilo Zerit, je treba pogosto spremljati zaradi možnosti pojava simptomov lipoatrofije.
Patients receiving zoledronic acid 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24.
Bolniki, ki so prejemali zoledronsko kislino 4 mg, so poročali o manjšem povečanju bolečine, kot bolniki, ki so prejemali placebo, razlika pa je postala značilna v 3., 9., 21. in 24 mesecu.
Patients receiving Zydelig should also be monitored for signs of infection and have regular blood tests to measure the level of white blood cells.
Bolnike, ki prejemajo zdravilo Zydelig, je treba spremljati za pojav znakov okužbe in pri njih redno opravljati krvne preiskave za merjenje ravni belih krvnih celic.
Patients refractory to fludarabine and alemtuzumab
Bolniki, pri katerih je bolezen neodzivna na zdravljenje s fludarabinom in alemtuzumabom
Patients remained on stable doses of NSAIDs and or prednisone ( 0.2 mg /kg/day or 10 mg/day maximum).
Bolniki so ostali na stabilnih odmerkih nesteroidnih protivnetnih zdravil in/ali prednizona ( 0,2 mg/kg/dan ali največ 10 mg/dan).
Patients reported improved health-related quality of life (QoL).
Bolniki so poročali o izboljšanju kvalitete življenja (QoL).
Patients requiring a dose less than 40 mg should use the 40 mg vial presentation of Humira.
Bolniki, ki potrebujejo odmerek manjši od 40 mg, naj uporabijo zdravilo Humira 40 mg v viali.
Patients requiring a dose less than 40 mg should use the 40mg vial presentation of Humira.
Bolniki, ki potrebujejo odmerek manjši od 40 mg, naj uporabijo zdravilo Humira 40 mg v viali.
Patients requiring a titrated daily dose> 8 mg buprenorphine /day may not find this regimen adequate.
Ta režim odmerjanja morda ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek > 8 mg buprenorfina/dan.
Patients requiring a titrated daily dose> 8 mg buprenorphine /day may not find this regimen adequate.
Ta režim odmerjanja ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek > 8 mg buprenorfina/dan.
Patients requiring a titrated daily dose> 8 mg buprenorphine/day may not find this regimen adequate.
Ta režim odmerjanja ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek > 8 mg buprenorfina/dan.
Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.
Pri bolnikih, ki potrebujejo večje znižanje LDL-H (> 60 %), je zdravljenje mogoče začeti s 150 mg subkutano enkrat na 2 tedna ali s 300 mg subkutano enkrat na 4 tedne (mesečno).
Patients responding to 8/10-weeks of acute treatment with open-label Thymanax 25-50 mg once daily were randomised to either Thymanax 25-50 mg once daily or placebo for further 6-months.
Bolnike, ki so se odzivali na odprto 8- do 10-tedensko akutno zdravljenje z zdravilom Thymanax v odmerku 25 do 50 mg enkrat na dan, so naključno razvrstili v skupino, ki je prejemala zdravilo Thymanax v odmerku 25 do 50 mg enkrat na dan ali skupino, ki je prejemala placebo nadaljnjih 6 mesecev.
Patients responding to 8/10-weeks of acute treatment with open-label Valdoxan 25-50 mg once daily were randomised to either Valdoxan 25-50 mg once daily or placebo for further 6-months.
Bolnike, ki so se odzivali na odprto 8- do 10-tedensko akutno zdravljenje z zdravilom Valdoxan v odmerku 25 do 50 mg enkrat na dan, so naključno razvrstili v skupino, ki je prejemala zdravilo Valdoxan v odmerku 25 do 50 mg enkrat na dan ali skupino, ki je prejemala placebo nadaljnjih 6 mesecev.
Patients scheduled for surgery on the day after injection will receive 74 MBq technetium Tc 99m labelled product.
Bolniki, pri katerih načrtujejo kirurški poseg dan po injiciranju, bodo prejeli zdravilo, označeno s tehnecijem Tc99m, z aktivnostjo 74 MBq.
Patients scheduled for surgery on the day of injection will receive 18.5 MBq technetium Tc 99m labelled product.
Bolniki, pri katerih načrtujejo kirurški poseg isti dan, bodo prejeli zdravilo, označeno s tehnecijem Tc99m, z aktivnostjo 18,5 MBq.
Patients seropositive to Rheumatoid Factor (RF) and/or anti- Cyclic Citrullinated Peptide (anti-CCP) who were treated with MabThera in combination with methotrexate showed an enhanced response compared to patients negative to both.
Bolniki, serološko pozitivni za revmatoidni faktor (RF) in/ali anti-ciklični citrulinirani peptid (anti- CCP), ki so prejemali zdravilo MabThera v kombinaciji z metotreksatom, so imeli izrazitejši odziv kot bolniki, negativni za oba.
Patients seropositive to Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (anti-CCP) who were treated with MabThera in combination with methotrexate showed an enhanced response compared to patients negative to both.
Bolniki, serološko pozitivni za revmatoidni faktor (RF) in/ali anti-ciklični citrulinirani peptid (anti- CCP), ki so prejemali zdravilo MabThera v kombinaciji z metotreksatom, so imeli izrazitejši odziv kot bolniki, negativni za oba.
Patients should also be advised that they might experience undesirable effects associated with co- administered medications.
Bolnikom je treba tudi povedati, da lahko izkusijo neželene učinke, povezane s sočasnim dajanjem drugih zdravil.
Patients should also be advised to rinse their mouth with water after inhaling (see section 4.4)
Bolnikom svetujte tudi, naj si po inhaliranju sperejo usta z vodo (glejte poglavje 4.4).
Patients should also be advised to rinse their mouth with water and spit the water out, and/or brush their teeth after inhaling (see section 4.4)
Bolnikom je treba svetovati tudi, naj si po inhaliranju usta izplaknejo z vodo, ki naj jo nato izpljunejo, in/ali oščetkajo zobe (glejte poglavje 4.4)
Patients should also receive antibiotic eye drops before and after injection and they should be monitored after the injection to check for infection or raised eye pressure.
Pred injiciranjem in po njem mora bolnik prejeti tudi antibiotik v obliki kapljic za oko, po injiciranju pa ga je treba nadzorovati, ker lahko nastopita okužba ali povišan očesni tlak.
Patients should also receive appropriate treatment to control uric acid levels in the blood.
Bolniki morajo prejeti tudi ustrezna zdravila za nadzor koncentracije sečne kisline v krvi.
Patients should also receive chemotherapy medicines injected in the spine area to prevent the leukaemia cells from growing back in the nervous system.
Bolnikom je prav tako treba v hrbtenico injicirati kemoterapevtska zdravila, da bi preprečili ponovno rast levkemičnih celic v živčevju.
Patients should also take a daily dose of 75 - 100 mg ASA or a daily dose of 75 - 100 mg ASA in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.
Bolniki naj jemljejo tudi dnevni odmerek 75 - 100 mg acetilsalicilne kisline ali dnevni odmerek 75 - 100 mg acetilsalicilne kisline poleg dnevnega odmerka 75 mg klopidogrela ali standardnega dnevnega odmerka tiklopidina.
Patients should also take calcium supplements if they are not getting enough calcium from their diet.
Bolnice morajo jemati tudi dodatke kalcija, če njegov vnos s prehrano ni zadosten.
Patients should also take calcium supplements if they are not getting enough calcium from their diet.
Bolniki morajo jemati tudi dodatke kalcija, če njegov vnos s prehrano ni zadosten.
Patients should also take calcium supplements if they are not getting enough calcium from their diet.
Jemati morajo tudi dodatke kalcija, če njegov vnos s prehrano ni zadosten.
Patients should always be pre-medicated 30 minutes to 2 hours prior to Arzerra infusion according to the following dosing schedules:
Bolniki morajo od 30 minut do 2 uri pred infundiranjem zdravila Arzerra vedno dobiti premedikacijo po naslednji shemi:
Patients should always take Rapamune consistently, either with or without food.
Zdravilo mora jemati redno, s hrano ali brez nje.
Patients should avoid being exposed to light for 60-90 days post-exposure. all patients should know that UV blocking is not effective in blocking visible light which activates porfimer.
Bolniki se ne smejo izpostavljati svetlobi 60-90 dni po injiciranju.
Patients should avoid consumption of any medicinal products containing methylxanthines as well as any medicinal products containing theophylline for at least 12 hours before Rapiscan administration (see section 4.2).
Bolniki naj se vsaj 12 ur pred dajanjem zdravila Rapiscan izognejo uživanju vsakršnih zdravil, ki vsebujejo metilksantine, pa tudi zdravil, ki vsebujejo teofilin (glejte poglavje 4.2).
Patients should avoid driving or operating machinery if symptoms of confusional state, somnolence, syncope, and/or dizziness are experienced.
Bolniki naj se izogibajo voţnji ali upravljanju s stroji, če se pojavijo simptomi zmedenosti, zaspanosti, sinkope in/ali omotice.
Patients should be
Bolnike je treba
Patients should be advised never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of the treatment.
Bolnikom je treba svetovati, da nikoli ne dajo svojega zdravila drugim in da po koncu zdravljenja vrnejo neuporabljene kapsule farmacevtu.
Patients should be advised not to breast feed if they are taking aripiprazole.
Bolnicam je treba svetovati, naj ne dojijo, če jemljejo aripiprazol.
Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Bolnicam, ki jemljejo olanzapin, naj se dojenje dojenčka odsvetuje.
Patients should be advised not to drive a car or to operate other potentially hazardous machines until they are familiar with the effects of brivaracetam on their ability to perform such activities.
Bolnikom je treba svetovati, naj ne vozijo avta ali uporabljajo drugih potencialno nevarnih strojev, dokler niso seznanjeni z učinki brivaracetama na njihovo sposobnost opravljanja takih dejavnosti.
Patients should be advised not to drive and use machines if they experience headache or vertigo.
Bolnikom je treba svetovati, naj ne vozijo ali upravljajo strojev, če se pri njih pojavi glavobol ali vrtoglavica.
Patients should be advised not to drive or operate machinery if they experience dizziness while taking SIRTURO.
Bolnike je treba opozoriti, naj ne vozijo in ne upravljajo strojev, če v času zdravljenja z zdravilom SIRTURO čutijo omotičnost.
Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance while taking Effentora and not to drive or operate machinery until they know how they react.
Bolnikom je treba svetovati, naj ne vozijo in ne upravljajo strojev, če čutijo zaspanost, omotičnost ali opazijo motnje vida pri jemanju zdravila Effentora, in da naj ne vozijo ali upravljajo strojev, dokler ne poznajo svojega odziva.
Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, visual disturbances or other adverse reaction which can impair their ability to drive and operate machinery.
Bolnikom je treba svetovati, da ne vozijo ali upravljajo strojev, če čutijo zaspanost, omotico, motnje vida ali druge neželene učinke, ki lahko poslabšajo njihovo sposobnost za vožnjo ali upravljanje s stroji.
Patients should be advised not to drive or operate machines if they experience confusion or somnolence or other adverse reactions which can impair their ability to drive or operate machines.
Bolnikom moramo svetovati, naj ne vozijo ali upravljajo s stroji, če se pri njih pojavijo zmedenost, zaspanost ali drugi neželeni učinki, ki lahko ovirajo sposobnost vožnje ali upravljanja s stroji.
Patients should be advised not to drive or operate machines, if dizziness is experienced while taking Siklos.
Bolnikom je treba svetovati, naj ne vozijo avtomobila in ne upravljajo s stroji, če imajo vrtoglavico, kadar jemljejo zdravilo Siklos.
Patients should be advised not to drive or operate machines, if dizziness is experienced while taking Siklos.
Bolnikom je treba svetovati, naj ne vozijo avtomobila in ne upravljajo z orodji ali stroji, če imajo vrtoglavico, kadar jemljejo zdravilo Siklos.
Patients should be advised not to swallow the desiccant capsule found in the bottle.
Bolnike je potrebno opozoriti, naj ne zaužijejo kapsule s sušilnim sredstvom, ki se nahaja v plastenki.
Patients should be advised not to use any tablets showing signs of deterioration, and caregivers to wear disposable gloves when handling the tablets.
Bolnikom je treba svetovati, naj ne uporabljajo tablet, ki kažejo znake kvarjenja, skrbnikom pa, naj med rokovanjem s tabletami uporabljajo rokavice za enkratno uporabo.
Patients should be advised of the need to take Viramune every day as prescribed.
Bolnike je treba poučiti, da morajo jemati zdravilo Viramune vsak dan, tako kot je predpisano.
Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions (see section 4.8).
Bolnike je treba poučiti o znakih in simptomih ter pozorno spremljati simptome alergijskih/preobčutljivostnih reakcijah (glejte poglavje 4.8).
Patients should be advised of the signs and symptoms of fibrosing colonopathy and to alert the treating physician if they develop any.
bolnike je treba poučiti o znakih in simptomih fibrozirajoče kolonopatije, o katerih morajo poročati svojemu zdravniku, če jih opazijo;
Patients should be advised of, and avoid exposure to, potential risk factors for infection as appropriate.
Bolnike poučite o potencialnih dejavnikih tveganja za okužbe glede na primer in jim svetujte, naj se jim izogibajo.
Patients should be advised that depigmentation of the hair or skin may also occur during treatment with sunitinib.
Bolnikom je treba svetovati, da lahko med zdravljenjem s sunitinibom pride do depigmentacije las in dlak ali kože.
Patients should be advised that dolutegravir or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection.
Bolnike je treba opozoriti, da dolutegravir ali katera koli druga protiretrovirusna terapija ne ozdravi okužbe s HIV in da se lahko pri njih vseeno pojavijo oportunistične okužbe in drugi s HIV povezani zapleti.
Patients should be advised that during treatment with CellCept, vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5).
Bolnike, ki prejemajo zdravilo CellCept, moramo opozoriti, da so lahko cepiva manj učinkovita, uporabi živih cepiv pa se morajo izogibati (glejte poglavje 4.5).
Patients should be advised that during treatment with Myclausen, vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5).
Bolnike, ki prejemajo zdravilo Myclausen, moramo opozoriti, da so lahko cepiva manj učinkovita, uporabi živih cepiv pa se morajo izogibati (glejte poglavje 4.5).
Patients should be advised that hypersensitivity reactions are possible on the day of, or the day after infusion, and be informed of potential signs and symptoms and the possibility of recurrence.
Bolnikom je treba povedati, da so preobčutljivostne reakcije možne na dan infundiranja ali dan po infundiranju, in jih seznaniti z možnimi znaki in simptomi in o možnosti ponovitve.
Patients should be advised that they may experience undesirable effects such as dizziness,blurred vision or somnolence during treatment with imatinib.
Bolnikom je treba razložiti, da lahko med zdravljenjem z imatinibom doživijo neželene učinke, na primer vrtoglavost, meglen vid ali somnolenco.
Patients should be advised that treatment with Telzir, or any other current antiretroviral therapy, does not cure HIV and that they may still develop opportunistic infections and other complications of HIV infection.
Bolnike je potrebno opozoriti, da zdravljenje z zdravilom Telzir ali s katerim koli drugim trenutno razpoložljivim protiretrovirusnim zdravljenjem okužbe z virusom HIV ne ozdravi, zato so še vedno možne oportunistične okužbe in drugi zapleti, povezani z okužbo z virusom HIV.
Patients should be advised that treatment with Torisel may be associated with an increase in blood glucose levels in diabetic and non-diabetic patients.
Bolnike je treba opozoriti, da je lahko zdravljenje z zdravilom Torisel povezano z zvečano koncentracijo glukoze v krvi tako pri diabetikih kot nediabetikih.
Patients should be advised to adhere strictly to a calorie- controlled diet.
Bolnikom je treba svetovati, da se strogo držijo kalorijsko kontrolirane diete.
Patients should be advised to be cautious when driving or using machines during treatment with Vargatef.
Bolnikom je treba svetovati, naj bodo med vožnjo ali upravljanjem s stroji med zdravljenjem z zdravilom Vargatef previdni.
Patients should be advised to be cautious when driving or using machines if they experience fatigue during treatment with Votubia.
Bolnike je treba opozoriti, naj bodo previdni pri vožnji in upravljanju s stroji, če pri njih v času zdravljenja z zdravilom Votubia prihaja do utrujenosti.
Patients should be advised to be cautious when driving or using machines if they experience fatigue or headache during treatment with Signifor.
Bolnikom je treba svetovati previdnost pri vožnji ali upravljanju s stroji, če so med zdravljenjem z zdravilom Signifor utrujeni ali imajo glavobol.
Patients should be advised to carefully read them.
Bolnikom je potrebno svetovati, naj jih natančno preberejo.